Redeye provides an update on Acarix following its Q1 report, which showed continued growth in revenues and installed systems—albeit below our expectations. We update our estimates taking a more cautious stance, assuming more growth capital will be required before the company becomes self-sustaining. We believe the absence of fixed reimbursement from private and public payors in the US remains a key bottleneck for the sales growth trajectory. We update our fair value range accordingly.
LÄS MER
